This article is more than 5 years old. Information may no longer be current.

SurgiMend acellular dermal matrix has lower gross complication rate than Epiflex

In a head-to-head comparison of acellular dermal matrices in breast reconstruction, researchers preferred SurgiMend which had fewer gross complications then Epiflex.

The retrospective review resulted from a single surgeon’s 6 year experience with both SurgiMend PRS (TEI, Biosciences Inc.) and Epiflex (Deutsches Institut für Zell- und Geedbeersatz gGmbH).

Among the 127 reconstructions performed, 63 surgical sites received SurgiMend and 64 received Epiflex.

In the SurgiMend group, 57 surgeries were oncological interventions and six were aesthetic procedures. The Epiflex group included 54 oncological interventions and 10 aesthetic procedures.

Researchers found no significant differences in smoking habits, prior chemotherapy, or prior radiation treatment. Average patient age and patient BMI also did not differ significantly.

Gross complication rates reported in the SurgiMend group accounted for 11.1% or seven of the 63 patients compared with 40.6%, or 26 of 64 Epiflex patients. – by Abigail Sutton

Disclosure: The researchers reported no relevant financial disclosures.